title: A longitudinal study of motor performance and striatal [18F]fluorodopa uptake in Parkinson's disease.
abstract: Although [(18)F]fluoro-L: -dopa [FDOPA] positron emission tomography (PET) has been used as a surrogate outcome measure in Parkinson's disease therapeutic trials, this biomarker has not been proven to reflect clinical status longitudinally. We completed a retrospective analysis of relationships between computerized sampling of motor performance, FDOPA PET, and clinical outcome scales, repeated over 4 years, in 26 Parkinson's disease (PD) patients and 11 healthy controls. Mixed effects analyses showed that movement time and tongue strength best differentiated PD from control subjects. In the treated PD cohort, motor performance measures changed gradually in contrast to a steady decline in striatal FDOPA uptake. Prolonged reaction and movement time were related to lower caudate nucleus FDOPA uptake, and abnormalities in hand fine force control were related to mean striatal FDOPA uptake. These findings provide evidence that regional loss of nigrostriatal inputs to frontostriatal networks affects specific aspects of motor function.
authors.affiliation: William S. Middleton Memorial Veterans Hospital, Madison, WI 53792, USA. gallagher@neurology.wisc.edu
authors.forename: Catherine L
authors.initials: CL
authors.lastname: Gallagher
authors.forename: Sterling C
authors.initials: SC
authors.lastname: Johnson
authors.forename: Barbara B
authors.initials: BB
authors.lastname: Bendlin
authors.forename: Moo K
authors.initials: MK
authors.lastname: Chung
authors.forename: James E
authors.initials: JE
authors.lastname: Holden
authors.forename: Terrence R
authors.initials: TR
authors.lastname: Oakes
authors.forename: Benjamin R
authors.initials: BR
authors.lastname: Brooks
authors.forename: Richard A
authors.initials: RA
authors.lastname: Konopacki
authors.forename: Selami
authors.initials: S
authors.lastname: Dogan
authors.forename: James H
authors.initials: JH
authors.lastname: Abbs
authors.forename: Guofan
authors.initials: G
authors.lastname: Xu
authors.forename: Robert J
authors.initials: RJ
authors.lastname: Nickles
authors.forename: Robert W
authors.initials: RW
authors.lastname: Pyzalski
authors.forename: Onofre T
authors.initials: OT
authors.lastname: Dejesus
authors.forename: W Douglas
authors.initials: WD
authors.lastname: Brown
mesh_terms: D000368:Aged; D000375:Aging / Q000502:physiology; D000978:Antiparkinson Agents / Q000627:therapeutic use; D002230:Carbidopa / Q000627:therapeutic use; D002421:Caudate Nucleus / Q000000981:diagnostic imaging / Q000378:metabolism; D003342:Corpus Striatum / Q000000981:diagnostic imaging* / Q000378:metabolism*; D004295:Dihydroxyphenylalanine / Q000031:analogs & derivatives* / Q000493:pharmacokinetics; D005260:Female; D018737:Hand Strength / Q000502:physiology; D006801:Humans; D007537:Isometric Contraction / Q000502:physiology; D007980:Levodopa / Q000627:therapeutic use; D008137:Longitudinal Studies; D008297:Male; D008875:Middle Aged; D053580:Muscle Strength / Q000502:physiology; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000000981:diagnostic imaging* / Q000378:metabolism*; D049268:Positron-Emission Tomography; D011597:Psychomotor Performance / Q000502:physiology*; D019275:Radiopharmaceuticals / Q000493:pharmacokinetics; D011930:Reaction Time / Q000502:physiology; D012189:Retrospective Studies; D012727:Sex Characteristics; D014059:Tongue / Q000502:physiology
chemical_list: D000978:Antiparkinson Agents; D019275:Radiopharmaceuticals; C029112:5-fluorodopa; D007980:Levodopa; D004295:Dihydroxyphenylalanine; D002230:Carbidopa